Bioventus Inc. (BVS) fair value analysis
Nasdaq · Updated 2026-10-19
BVS price how computed
Forward Fair Value verdict
Fairly valuedBVS is trading at within about 10% of estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $13.30
- Sector
- Healthcare
- 12-month range
- $6.53–$15.26
- Market cap
- $908M
- From 52-week high
- -12.8%
- Shares outstanding
- 68.3M
- Rank in Healthcare by discount to fair value
- #67 of 108
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Bioventus Inc. is a healthcare company that develops and commercializes orthopedic solutions, including products for joint preservation and regenerative medicine. The company operates primarily in the United States and internationally through its portfolio of surgical and non-surgical treatments for musculoskeletal conditions.
BVS currently ranks #67 of 108 Healthcare stocks by discount to fair value. It has screened as Fairly valued for 5 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $908M
- P/E (trailing)
- 18x
- Revenue (TTM)
- $582M
- Net margin
- 9.4%
- EPS (TTM)
- $0.76
- Gross margin
- 69.0%
- Debt / equity
- 1.16
- Revenue growth (3-yr avg)
- 8.9%
- Shares outstanding
- 68.3M
Derived indicators how computed
- Quality grade
- B
- Margin trend
- Stable
- 52-week position
- The top quarter of its range
Technicals how computed
- RSI (14-day)
- 55 · neutral
- 50-day average
- $13.66
- 200-day average
- $10.57
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-03
- Last 8 quarters vs consensus
- 7 beat, 0 missed
- Quarter by quarter
- 2026-06 ▬ met (0.0%)
2026-03 ▲ beat (+114.3%)
2025-12 ▲ beat (+17.5%)
2025-09 ▲ beat (+25.0%)
2025-06 ▲ beat (+5.0%)
2025-03 ▲ beat (+300.0%)
2024-12 ▲ beat (+76.5%)
2024-09 ▲ beat (+200.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 5 buy · 0 hold · 0 sell (5 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $17.6
- Target vs last price
- +32.3%
What our data shows for BVS
- Our model validated 13 trailing price-to-earnings windows for BVS, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $6.53–$15.26.
- The 14-day relative strength index sits at a neutral 55.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for BVS
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent BVS news
TickrTrends' derived news-sentiment signal for BVS is currently leaning positive, computed from recent coverage.
- Bioventus Inc (BVS) Stock Up 3.6% but GF Value Says Overvalued -- GF Score: 63/100 (gurufocus.com, 2026-10-13)
TickrTrends take: Bioventus Inc operates in the Healthcare sector where valuation metrics warrant careful monitoring. While the stock recently gained 3 percent in price movement, TickrTrends' assessment of fair valuation contrasts with the GF Value indicator's overvalued signal, suggesting investors should track whether the company's fundamentals can support current pricing levels. A GF Score of 63 indicates moderate quality, which makes the divergence between fair value and overvalued assessments a key point for shareholders to evaluate as new financial data emerges. - Juniper Investment Company, LLC Adds Orthofix Medical Inc (OFIX) -- Shares Look 30% Undervalued on GF Value (gurufocus.com, 2026-09-29)
TickrTrends take: Juniper Investment Company's recent addition of Orthofix Medical suggests institutional confidence in orthopedic device valuations that may present contrasting opportunities in the healthcare sector. While TickrTrends currently assesses BVS as overvalued, the market's apparent appetite for undervalued healthcare equities like Orthofix indicates that valuation discrepancies within medical device and healthcare subsectors warrant careful monitoring. Investors focused on valuation metrics should track whether BVS shares adjust toward fair value or if the broader healthcare sector continues to show pockets of undervaluation that differentiate individual names. - Bioventus: Cash Flow Anchors The Bull Case Beyond A Potential Sale (NASDAQ:BVS) (seekingalpha.com, 2026-09-21)
TickrTrends take: Bioventus trades at a valuation that TickrTrends currently assesses as overvalued, which contrasts with the positive cash flow dynamics highlighted in recent analysis. For investors focused on valuation metrics, the company's ability to generate cash becomes particularly important to monitor, as it may eventually justify a higher price if the market reprices the stock downward or fundamentals strengthen materially. The potential sale scenario referenced in the headline adds an additional variable to traditional valuation assessment, since transaction valuations can diverge significantly from public market prices.
What people are saying
Follow the BVS conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for BVS show improvement this week, with the company's quality grade rising from C to B. The Healthcare sector stock maintains a fairly valued status based on current valuation metrics.
- 2026-10-05 — BVS has experienced several notable shifts in its derived indicators over the past week. The 50/200-day trend state has moved from an uptrend to a mixed condition, while the stock's sector discount rank has improved from 87th to 82nd position within the Healthcare sector. The valuation verdict has shifted from Overvalued to Fairly valued, reflecting a more balanced assessment of the stock's current pricing relative to its fundamentals.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is BVS stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), BVS is trading at within about 10% of estimated fair value and screens as fairly valued. The exact fair value and discount are available to subscribers.
What is BVS's TickrTrends verdict?
BVS's current verdict is Fairly valued, refreshed with every weekly Forward Fair Value run.
How does BVS compare to other Healthcare stocks?
BVS ranks #67 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is BVS overbought or oversold?
BVS's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does BVS report earnings next?
BVS's next earnings report is scheduled for 2026-11-03, per the published earnings calendar.
Does BVS usually beat earnings estimates?
Over its last 8 reported quarters BVS beat the consensus estimate 7 times and missed 0 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about BVS?
Of 5 analysts covering BVS, 5 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $17.6 (+32.3% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
BVS vs A · BVS vs BMY · BVS vs ELV · BVS vs INMD · BVS vs LH